Post Melanocortin Comparison

The melanocortin system is one of the most pharmacologically diverse peptide targets in biomedical research — governing pigmentation, sexual function, appetite, inflammation, and immune regulation through a family of five G protein-coupled receptors (MC1R–MC5R). Exceed Enhancement stocks three melanocortin peptides with distinct receptor selectivity profiles: Melanotan-I (MT-I / Afamelanotide), Melanotan-II (MT-II), and PT-141 (Bremelanotide). Despite their structural similarities and shared melanocortin lineage, they differ substantially in receptor targeting, physiological effects, and research applications. This guide compares all three systematically. All content is for scientific and educational reference only; these compounds are not approved for human therapeutic use (with the exceptions noted below).

The Melanocortin System: A Primer

The melanocortin system originates with pro-opiomelanocortin (POMC) — a precursor protein cleaved into multiple bioactive peptides including ACTH (adrenocorticotropin), α-MSH, β-MSH, and γ-MSH. These endogenous melanocortins act at five receptors with distinct tissue distributions and functions:

• MC1R — Melanocytes (skin, hair follicles); regulates eumelanin vs. phaeomelanin synthesis; immune modulation; anti-inflammatory in macrophages
• MC2R — Adrenal cortex; exclusive receptor for ACTH; regulates cortisol synthesis
• MC3R — Hypothalamus, limbic system; energy homeostasis, feeding behavior, inflammation regulation
• MC4R — Widely expressed in CNS (hypothalamus, brainstem, spinal cord); sexual function, appetite suppression, erectile/genital arousal pathways, energy expenditure
• MC5R — Exocrine glands (sebaceous, lacrimal, salivary); immune modulation; fat metabolism in peripheral tissues

The endogenous agonist α-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) activates MC1R, MC3R, MC4R, and MC5R, but not MC2R. The synthetic melanocortin peptides in this guide are all cyclic or linear analogs of α-MSH designed to optimize specific receptor interactions.

Melanotan-I (MT-I / Afamelanotide)

Structure

Melanotan-I is a linear tridecapeptide analog of α-MSH: [Nle⁴, D-Phe⁷]-α-MSH. Two key modifications relative to native α-MSH — substitution of methionine at position 4 with norleucine (Nle, oxidation-resistant), and substitution of L-phenylalanine at position 7 with D-phenylalanine (D-Phe, protease-resistant) — produce a more stable, longer-acting compound than endogenous α-MSH while broadly maintaining the α-MSH receptor binding profile.

Receptor Profile

MT-I is a full agonist at MC1R, MC3R, MC4R, and MC5R. Its most clinically significant activity is at MC1R — driving melanogenesis (melanin synthesis and dispersion in melanocytes) more potently and durably than endogenous α-MSH.

Primary Research Applications

Photoprotection and pigmentation: MT-I’s defining research application is MC1R-mediated induction of eumelanin synthesis — producing UV-independent skin tanning that functions as a photoprotective mechanism. This is the basis for its most advanced clinical development: Afamelanotide (Scenesse) received European Medicines Agency (EMA) approval in 2014 and FDA approval in 2019 for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) — a rare disorder in which heme precursor accumulation causes severe photosensitivity. This makes MT-I the only melanocortin peptide with full regulatory approval as a marketed drug.

Photoprotection beyond EPP: MT-I has been studied in solar urticaria, polymorphic light eruption, and vitiligo repigmentation — all conditions where enhanced MC1R activity and melanin density provide clinical utility.

Anti-inflammatory activity via MC1R: MC1R is expressed on macrophages, dendritic cells, and other immune cells where its activation suppresses NF-κB signaling and pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β). MT-I’s potent MC1R agonism makes it a compound of interest in inflammatory skin disease and systemic inflammation research independent of its pigmentation effects.

Key distinguishing feature: MT-I’s primary research and clinical value lies in photoprotection and MC1R-mediated pigmentation biology. Its relatively limited CNS penetration and its MC4R activity (shared with MT-II and PT-141) are secondary considerations in most MT-I research contexts.

Melanotan-II (MT-II)

Structure

Melanotan-II is a cyclic heptapeptide: cyclo[Nle⁴, D-Phe⁷]-α-MSH(4–11). It retains the Nle⁴ and D-Phe⁷ modifications of MT-I, but is significantly truncated (7 vs. 13 residues) and cyclized via a disulfide-like lactam bridge — producing a compact, conformationally constrained structure with enhanced CNS penetration and altered receptor selectivity compared to the linear MT-I.

Receptor Profile

MT-II is a non-selective melanocortin agonist with high affinity at MC1R, MC3R, MC4R, and MC5R — similar breadth to MT-I, but with substantially greater CNS penetration due to its smaller, cyclic structure. The key functional difference is its more potent MC4R activation in the CNS relative to MT-I, which is the mechanistic basis for its prominent sexual arousal and appetite-suppressing effects.

Primary Research Applications

Sexual function — MC4R CNS pathway: MT-II was the first compound to demonstrate that MC4R activation in the CNS mediates erectile function and genital arousal — a discovery with significant implications for sexual dysfunction research. MC4R agonism in the hypothalamus and spinal cord activates downstream oxytocin release and pro-erectile spinal pathways, producing penile erection in rodent models independent of visual or tactile stimuli. This effect directly led to the development of PT-141 (Bremelanotide) as a more selective sexual function compound.

Pigmentation: Like MT-I, MT-II produces robust eumelanin synthesis via MC1R — though its use in pigmentation research has been largely superseded by MT-I (Afamelanotide) in clinical contexts given MT-I’s better-characterized photoprotective profile and regulatory approval.

Appetite suppression and energy balance: MC4R and MC3R activation in the hypothalamic arcuate nucleus and paraventricular nucleus reduces food intake and increases energy expenditure. MT-II’s hypothalamic MC4R activity produces anorectic effects in animal models — making it relevant to obesity and appetite regulation research, though with the confound of simultaneous sexual arousal pathway activation.

Key distinguishing feature: MT-II is a broad-spectrum melanocortin agonist with significant CNS activity at both sexual function (MC4R) and pigmentation (MC1R) pathways simultaneously. Its non-selectivity is both its strength (studying multiple pathways) and its research limitation (confounding of effects when isolating a specific receptor’s contribution).

PT-141 (Bremelanotide)

Structure

PT-141 is a cyclic heptapeptide metabolite of MT-II: it differs by a single modification — replacement of the MT-II C-terminal amide with a hydroxyl group (serine). This seemingly minor change produces a compound that retains strong MC4R and MC3R activity but has significantly reduced MC1R activity relative to MT-II — dramatically reducing the pigmentation/tanning effect while maintaining sexual function activity.

Receptor Profile

PT-141 primarily activates MC4R and MC3R; its MC1R activity is substantially attenuated compared to MT-II. This makes PT-141 functionally selective for CNS melanocortin pathways — sexual function, appetite, energy balance — without the prominent melanogenic activity of MT-I or MT-II.

Primary Research Applications

Sexual dysfunction — the primary clinical application: PT-141 is the only melanocortin peptide to receive FDA approval for a sexual dysfunction indication — approved in 2019 as Vyleesi (bremelanotide injection, 1.75 mg) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (sildenafil, tadalafil) that work peripherally via NO/cGMP-mediated vasodilation, PT-141 works centrally — acting on melanocortin receptors in hypothalamic nuclei to increase sexual motivation and arousal through CNS pathways rather than simply improving genital blood flow. This mechanistic distinction makes PT-141 uniquely relevant to research on central (desire/motivation) vs. peripheral (vascular) sexual dysfunction pathways.

Regulatory status: PT-141 (Vyleesi) has FDA approval specifically for HSDD in premenopausal women. Research in male erectile dysfunction, post-SSRI sexual dysfunction, and other hypoactive desire presentations continues in preclinical and early clinical settings.

Appetite and energy balance: MC4R and MC3R activation produce anorectic effects consistent with MT-II — but without the pigmentation confound. PT-141 has been studied in obesity and appetite regulation research where clean MC4R agonism is desired without melanogenic side effects.

Key distinguishing feature: PT-141 is the most receptor-selective of the three for CNS MC4R/MC3R activity, minimizing off-target pigmentation and providing the cleanest sexual function and appetite research profile. Its FDA approval for HSDD represents the most advanced clinical validation of any compound in this group for its specific indication.

Head-to-Head Comparison

Choosing the Right Compound for Your Research

If your research targets pigmentation, photoprotection, or MC1R biology: Melanotan-I is the preferred compound — highest MC1R potency, most clinically validated for pigmentation, FDA-approved for EPP. Minimizes CNS/sexual confounds.

If your research requires studying multiple melanocortin pathways simultaneously (pigmentation + sexual function + appetite): Melanotan-II — broad-spectrum agonist with both peripheral (MC1R/pigmentation) and central (MC4R/sexual) activity.

If your research targets CNS MC4R (sexual function, desire, appetite) while minimizing pigmentation confounds: PT-141 — most selective for MC4R/MC3R CNS activity, FDA-approved for HSDD, and appropriate for research requiring clean separation of central melanocortin effects from peripheral pigmentation.

Storage and Reconstitution

All three compounds are lyophilized peptide powders. Standard storage recommendations for research use:

• Store lyophilized powder at −20°C for long-term; 2–8°C acceptable short-term
• Reconstitute with bacteriostatic water or sterile saline
• After reconstitution: refrigerate at 2–8°C, protect from light, use within 30 days
• Do not freeze reconstituted solutions

Disclaimer

Melanotan-I, Melanotan-II, and PT-141 are sold strictly for in vitro and preclinical research purposes unless otherwise specified. MT-I (Scenesse) and PT-141 (Vyleesi) exist as approved pharmaceutical products for specific indications; the research-grade compounds described here are not equivalent to those approved formulations and are not intended for human therapeutic use. This content is for scientific and educational informational purposes only.

References

• Hadley ME, Dorr RT. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies, and commercialization. Peptides, 27(4), 921–930.
• Cone RD. (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews, 27(7), 736–749.
• Wessells H, et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology, 160(2), 389–393.
• Diamond LE, et al. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141. International Journal of Impotence Research, 16(1), 51–59.
• Clayton AH, et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women. Obstetrics & Gynecology, 128(3), 536–547.
• Langan EA, et al. (2010). The role of melanocortins in dermatology and inflammatory skin disease. British Journal of Dermatology, 163(3), 449–458.
• Harms JH, et al. (2009). Mitigation of erythropoietic protoporphyria-related pain by afamelanotide. Journal of Hepatology, 51(6), 1027–1033.